

Peter Verhamme

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1772056/publications.pdf>

Version: 2024-02-01

176
papers

13,080
citations

71061

41
h-index

24232

110
g-index

177
all docs

177
docs citations

177
times ranked

12889
citing authors

#	ARTICLE	IF	CITATIONS
1	Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. <i>European Respiratory Journal</i> , 2022, 59, 2101724.	3.1	38
2	Reduced-Dose Intravenous Thrombolysis for Acute Intermediate- to High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International Thrombolysis (PEITHO)-3 trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 857-866.	1.8	35
3	Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study. <i>Thrombosis and Haemostasis</i> , 2022, 122, 646-656.	1.8	25
4	Aspirin use is associated with increased risk for incident heart failure: a patient-level pooled analysis. <i>ESC Heart Failure</i> , 2022, 9, 685-694.	1.4	10
5	A RIETE registry analysis of patients with upper extremity deep vein thrombosis and thoracic outlet syndrome. <i>Thrombosis Research</i> , 2022, 213, 65-70.	0.8	4
6	The novel proteomic signature for cardiac allograft vasculopathy. <i>ESC Heart Failure</i> , 2022, 9, 1216-1227.	1.4	8
7	Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO). <i>ERJ Open Research</i> , 2022, 8, 00610-2021.	1.1	5
8	<i>Staphylococcus aureus</i> and Neutrophil Extracellular Traps: The Master Manipulator Meets Its Match in Immunothrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 261-276.	1.1	21
9	Open-Angle Glaucomatous Optic Neuropathy Is Related to Dips Rather Than Increases in the Mean Arterial Pressure Over 24-H. <i>American Journal of Hypertension</i> , 2022, 35, 703-714.	1.0	5
10	Apixaban in a porcine model of mechanical valve thrombosis in pulmonary position—a pilot study. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2022, 35, .	0.5	2
11	Thromboprophylaxis in COVID-19: Weight and severity adjusted intensified dosing. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12683.	1.0	4
12	Association of colorectal cancer with genetic and epigenetic variation in PEARL—a population-based cohort study. <i>PLoS ONE</i> , 2022, 17, e0266481.	1.1	1
13	Mechanical properties and cellular content of leukocyte- and platelet-rich fibrin membranes of patients on antithrombotic drugs. <i>Journal of Periodontal Research</i> , 2022, , .	1.4	4
14	Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 786-795.	1.4	6
15	Prevalence of Acute Pulmonary Embolism at Autopsy in Patients With COVID-19. <i>American Journal of Cardiology</i> , 2022, 171, 159-164.	0.7	13
16	Urinary Proteomic Profile of Arterial Stiffness Is Associated With Mortality and Cardiovascular Outcomes. <i>Journal of the American Heart Association</i> , 2022, 11, e024769.	1.6	9
17	Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis. <i>Circulation</i> , 2022, 145, 1875-1877.	1.6	1
18	Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12748.	1.0	2

#	ARTICLE	IF	CITATIONS
19	Treatment of cancer-associated thrombosis: The evolution of anticoagulant choice and clinical insights into practical management. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103125.	2.0	11
20	Association of Fatal and Nonfatal Cardiovascular Outcomes With 24-Hour Mean Arterial Pressure. <i>Hypertension</i> , 2021, 77, 39-48.	1.3	24
21	Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirusâ€² (SARSâ€²CoVâ€²) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies. <i>British Journal of Haematology</i> , 2021, 192, 1100-1105.	1.2	51
22	Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2â€²azithromycin trial. <i>Trials</i> , 2021, 22, 126.	0.7	10
23	Diastolic left ventricular function in relation to the retinal microvascular fractal dimension in a Flemish population. <i>Hypertension Research</i> , 2021, 44, 446-453.	1.5	0
24	Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1097-1106.	1.8	14
25	Maxillofacial and oral surgery in patients with thrombophilia: safe territory for the oral surgeon? A single-center retrospective study. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2021, 132, 514-522.	0.2	1
26	Non-invasive early exclusion of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: the InShape II study. <i>Thorax</i> , 2021, 76, 1002-1009.	2.7	41
27	Relative and Absolute Risk to Guide the Management of Pulse Pressure, an Age-Related Cardiovascular Risk Factor. <i>American Journal of Hypertension</i> , 2021, 34, 929-938.	1.0	15
28	Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial. <i>EBioMedicine</i> , 2021, 66, 103288.	2.7	21
29	Tranexamic acid and bleeding in patients treated with non-vitamin K oral anticoagulants undergoing dental extraction: The EXTRACT-NOAC randomized clinical trial. <i>PLoS Medicine</i> , 2021, 18, e1003601.	3.9	11
30	Two-Year Responses of Heart Rate and Heart Rate Variability to First Occupational Lead Exposure. <i>Hypertension</i> , 2021, 77, 1775-1786.	1.3	7
31	Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy. <i>Stroke</i> , 2021, 52, 2096-2105.	1.0	25
32	Normal-tension glaucomatous optic neuropathy is related to blood pressure variability in the Maracaibo Aging Study. <i>Hypertension Research</i> , 2021, 44, 1105-1112.	1.5	7
33	Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12566.	1.0	3
34	Tranexamic acid for the prevention and treatment of bleeding in surgery, trauma and bleeding disorders: a narrative review. <i>Thrombosis Journal</i> , 2021, 19, 54.	0.9	33
35	Urinary proteomics combined with home blood pressure telemonitoring for health care reform trial: rationale and protocol. <i>Blood Pressure</i> , 2021, 30, 269-281.	0.7	8
36	Abelacimab for Prevention of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2021, 385, 609-617.	13.9	143

#	ARTICLE	IF	CITATIONS
37	Risk stratification of cardiovascular complications using CHA2DS2-VASc and CHADS2 scores in chronic atherosclerotic cardiovascular disease. <i>International Journal of Cardiology</i> , 2021, 337, 9-15.	0.8	4
38	Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3008-3017.	1.9	10
39	Rationale for azithromycin in COVID-19: an overview of existing evidence. <i>BMJ Open Respiratory Research</i> , 2021, 8, e000806.	1.2	49
40	Apixaban in patients on haemodialysis: a single-dose pharmacokinetics study. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 884-889.	0.4	7
41	Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine—A Multicenter Trial. <i>Thrombosis and Haemostasis</i> , 2020, 120, 132-140.	1.8	30
42	Central hemodynamics in relation to low-level environmental lead exposure. <i>Blood Pressure</i> , 2020, 29, 157-167.	0.7	3
43	Von Willebrand factor and ADAMTS13 impact on the outcome of <i>Staphylococcus aureus</i> sepsis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 722-731.	1.9	24
44	American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. <i>Blood Advances</i> , 2020, 4, 4693-4738.	2.5	636
45	Belgian clinical guidance on anticoagulation management in hospitalised and ambulatory patients with COVID-19. <i>Acta Clinica Belgica</i> , 2020, , 1-6.	0.5	12
46	Management and outcomes of cancer patients with venous thromboembolism presenting with thrombocytopenia. <i>Thrombosis Research</i> , 2020, 195, 139-145.	0.8	12
47	The Expression of von Willebrand Factor-Binding Protein Determines Joint-Invading Capacity of <i>Staphylococcus aureus</i> , a Core Mechanism of Septic Arthritis. <i>MBio</i> , 2020, 11, .	1.8	14
48	Non-vitamin K oral anticoagulants in adults with congenital heart disease: quod non?. <i>European Heart Journal</i> , 2020, 41, 4178-4180.	1.0	6
49	Retinal and Renal Microvasculature in Relation to Central Hemodynamics in 11-Year-Old Children Born Preterm or At Term. <i>Journal of the American Heart Association</i> , 2020, 9, e014305.	1.6	5
50	Cerebral small vessel diseases are better associated with ambulatory than office blood pressure measurements. <i>Alzheimer's and Dementia</i> , 2020, 16, e045987.	0.4	0
51	A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. <i>Trials</i> , 2020, 21, 981.	0.7	17
52	Different Types of Statins and All-Cause Mortality during Anticoagulation for Venous Thromboembolism: Validation Study from RIETE Registry. <i>TH Open</i> , 2020, 04, e236-e244.	0.7	6
53	Association between reperfusion therapy and outcomes in patients with acute pulmonary embolism and right heart thrombi. <i>European Respiratory Journal</i> , 2020, 56, 2000538.	3.1	6
54	Mechanical and structural properties of leukocyte- and platelet-rich fibrin membranes: An in vitro study on the impact of anticoagulant therapy. <i>Journal of Periodontal Research</i> , 2020, 55, 686-693.	1.4	7

#	ARTICLE	IF	CITATIONS
55	Cardiovascular End Points and Mortality Are Not Closer Associated With Central Than Peripheral Pulsatile Blood Pressure Components. <i>Hypertension</i> , 2020, 76, 350-358.	1.3	33
56	Clinical implications of incidental venous thromboembolism in cancer patients. <i>European Respiratory Journal</i> , 2020, 55, 1901697.	3.1	31
57	The Dangerous Liaisons between Chronic Obstructive Pulmonary Disease and Venous Thromboembolism. <i>Thrombosis and Haemostasis</i> , 2020, 120, 363-365.	1.8	4
58	Coagulation: At the heart of infective endocarditis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 995-1008.	1.9	59
59	Anticoagulation for Patients with Venous Thromboembolism: When is Extended Treatment Required?. <i>TH Open</i> , 2020, 04, e446-e456.	0.7	11
60	Urinary peptidomic biomarkers of renal function in heart transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1336-1343.	0.4	10
61	Definition of bleeding events in studies evaluating prophylactic antithrombotic therapy in pregnant women: A systematic review and a proposal from the ISTH SSC. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1979-1988.	1.9	15
62	Implementing Automated Office Blood Pressure Measurement. <i>Hypertension</i> , 2019, 74, 441-449.	1.3	5
63	Association of Office and Ambulatory Blood Pressure With Mortality and Cardiovascular Outcomes. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 409.	3.8	265
64	Intermittent pneumatic compression on top of pharmacological thromboprophylaxis in intensive care: added value or added cost?. <i>Journal of Thoracic Disease</i> , 2019, 11, 1734-1737.	0.6	4
65	Retinal Microvasculature in Relation to Central Hemodynamics in a Flemish Population. <i>Hypertension</i> , 2019, 74, 606-613.	1.3	10
66	Variation of PEAR1 DNA methylation influences platelet and leukocyte function. <i>Clinical Epigenetics</i> , 2019, 11, 151.	1.8	25
67	Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. <i>Thrombosis and Haemostasis</i> , 2019, 119, 576-585.	1.8	8
68	Vitamin K-Dependent Matrix Gla Protein as Multifaceted Protector of Vascular and Tissue Integrity. <i>Hypertension</i> , 2019, 73, 1160-1169.	1.3	33
69	A comprehensive report of long-term outcomes after catheter-directed thrombolysis for occluded infrainguinal bypass grafts. <i>Journal of Vascular Surgery</i> , 2019, 70, 1205-1216.	0.6	4
70	Central Hemodynamics in Relation to Circulating Desphospho-uncarboxylated Matrix Gla Protein: A Population Study. <i>Journal of the American Heart Association</i> , 2019, 8, e011960.	1.6	14
71	<i>Staphylococcus aureus</i> endocarditis: distinct mechanisms of bacterial adhesion to damaged and inflamed heart valves. <i>European Heart Journal</i> , 2019, 40, 3248-3259.	1.0	92
72	Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2019, 380, 1326-1335.	13.9	687

#	ARTICLE	IF	CITATIONS
73	Lemierre Syndrome: Clinical Update and Protocol for a Systematic Review and Individual Patient Data Meta-analysis. <i>Hamostaseologie</i> , 2019, 39, 076-086.	0.9	30
74	Local haemostatic measures after tooth removal in patients on antithrombotic therapy: a systematic review. <i>Clinical Oral Investigations</i> , 2019, 23, 1695-1708.	1.4	20
75	Renal function in relation to low-level environmental lead exposure. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 941-946.	0.4	11
76	Diastolic left ventricular function in relation to circulating metabolic biomarkers in a population study. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 22-32.	0.8	23
77	Rate and duration of hospitalisation for acute pulmonary embolism in the real-world clinical practice of different countries: analysis from the RIETE registry. <i>European Respiratory Journal</i> , 2019, 53, 1801677.	3.1	13
78	Idarucizumab for the reversal of dabigatran in patients undergoing heart transplantation. <i>European Journal of Heart Failure</i> , 2019, 21, 129-131.	2.9	10
79	Targeting Coagulase Activity in <i>Staphylococcus aureus</i> Bacteraemia: A Randomized Controlled Single-Centre Trial of Staphylothrombin Inhibition. <i>Thrombosis and Haemostasis</i> , 2018, 118, 818-829.	1.8	15
80	Conventional and Ambulatory Blood Pressure as Predictors of Diastolic Left Ventricular Function in a Flemish Population. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	5
81	Reproducibility of Retinal Microvascular Traits Decoded by the Singapore I Vessel Assessment Software Across the Human Age Range. <i>American Journal of Hypertension</i> , 2018, 31, 438-449.	1.0	8
82	Impact of Thrombus Sidedness on Presentation and Outcomes of Patients with Proximal Lower Extremity Deep Vein Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 341-347.	1.5	12
83	Epidemiologic observations guiding clinical application of a urinary peptidomic marker of diastolic left ventricular dysfunction. <i>Journal of the American Society of Hypertension</i> , 2018, 12, 438-447.e4.	2.3	20
84	Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2306-2315.	1.2	296
85	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>European Heart Journal</i> , 2018, 39, 1330-1393.	1.0	1,576
86	Association between cognition and the retinal microvasculature in 11-year old children born preterm or at term. <i>Early Human Development</i> , 2018, 118, 1-7.	0.8	20
87	Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent. <i>TH Open</i> , 2018, 02, e1-e7.	0.7	5
88	The risk of nephrolithiasis is causally related to inactive matrix Gla protein, a marker of vitamin K status: a Mendelian randomization study in a Flemish population. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 514-522.	0.4	15
89	ECG Voltage in Relation to Peripheral and Central Ambulatory Blood Pressure. <i>American Journal of Hypertension</i> , 2018, 31, 178-187.	1.0	12
90	Glomerular function in relation to circulating adhesion molecules and inflammation markers in a general population. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 426-435.	0.4	27

#	ARTICLE	IF	CITATIONS
91	Desphospho-uncarboxylated matrix Gla protein is a novel circulating biomarker predicting deterioration of renal function in the general population. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1122-1128.	0.4	33
92	Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2018, 378, 615-624.	13.9	1,237
93	Branched-Chain Amino Acids as Critical Switches in Health and Disease. <i>Hypertension</i> , 2018, 72, 1012-1022.	1.3	63
94	Inactive matrix Gla protein is a novel circulating biomarker predicting retinal arteriolar narrowing in humans. <i>Scientific Reports</i> , 2018, 8, 15088.	1.6	17
95	Early Use of Echocardiography in Patients With Acute Pulmonary Embolism: Findings From the RIETE Registry. <i>Journal of the American Heart Association</i> , 2018, 7, e009042.	1.6	31
96	Risk of recurrent venous thromboembolism according to baseline risk factor profiles. <i>Blood Advances</i> , 2018, 2, 788-796.	2.5	71
97	Shear Stress and VE-Cadherin. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 2174-2183.	1.1	25
98	Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1439-1449.	1.8	154
99	Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. <i>Thrombosis Research</i> , 2018, 168, 121-129.	0.8	11
100	Assessment of the Dual Role of Clumping Factor A in <i>S. Aureus</i> Adhesion to Endothelium in Absence and Presence of Plasma. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1230-1241.	1.8	23
101	Epidemiological and histological findings implicate matrix Gla protein in diastolic left ventricular dysfunction. <i>PLoS ONE</i> , 2018, 13, e0193967.	1.1	10
102	Validation of a prognostic score for hidden cancer in unprovoked venous thromboembolism. <i>PLoS ONE</i> , 2018, 13, e0194673.	1.1	16
103	D-Dimer Levels and Risk of Recurrence Following Provoked Venous Thromboembolism: Findings from the Riete Registry. <i>Blood</i> , 2018, 132, 3810-3810.	0.6	1
104	Left Ventricular Structure and Function in Relation to Environmental Exposure to Lead and Cadmium. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	42
105	Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. <i>Blood Pressure</i> , 2017, 26, 321-331.	0.7	20
106	Pragmatic approach to manage new oral anticoagulants in patients undergoing dental extractions: a prospective case-control study. <i>Clinical Oral Investigations</i> , 2017, 21, 2183-2188.	1.4	47
107	A Urinary Fragment of Mucin-1 Subunit $\hat{\pm}$ Is a Novel Biomarker Associated With Renal Dysfunction in the General Population. <i>Kidney International Reports</i> , 2017, 2, 811-820.	0.4	24
108	Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2017, 376, 1211-1222.	13.9	577

#	ARTICLE	IF	CITATIONS
109	Treatment of Right Heart Thrombi Associated with Acute Pulmonary Embolism. <i>American Journal of Medicine</i> , 2017, 130, 588-595.	0.6	45
110	Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker. <i>Kidney International Reports</i> , 2017, 2, 1066-1075.	0.4	77
111	Idarucizumab for Dabigatran Reversal – Full Cohort Analysis. <i>New England Journal of Medicine</i> , 2017, 377, 431-441.	13.9	858
112	Left ventricular function in relation to chronic residential air pollution in a general population. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1416-1428.	0.8	35
113	PEAR1 is not a major susceptibility gene for cardiovascular disease in a Flemish population. <i>BMC Medical Genetics</i> , 2017, 18, 45.	2.1	13
114	Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. <i>Thrombosis Research</i> , 2017, 149, 29-37.	0.8	14
115	Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2406-2414.	1.8	8
116	A Randomized, Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin for Venous Thromboembolism Associated with Cancer: Hokusai VTE-Cancer Study. <i>Blood</i> , 2017, 130, LBA-6-LBA-6.	0.6	6
117	Diastolic Left Ventricular Function in Relation to Circulating Metabolic Biomarkers in a General Population. <i>Journal of the American Heart Association</i> , 2016, 5, e002681.	1.6	16
118	Vitamin K Dependent Protection of Renal Function in Multi-ethnic Population Studies. <i>EBioMedicine</i> , 2016, 4, 162-169.	2.7	44
119	Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry. <i>Lancet Haematology</i> , 2016, 3, e267-e275.	2.2	55
120	Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. <i>Lancet Haematology</i> , 2016, 3, e437-e445.	2.2	29
121	Absence of Pear1 does not affect murine platelet function in vivo. <i>Thrombosis Research</i> , 2016, 146, 76-83.	0.8	10
122	Venous thromboembolism in centenarians: Findings from the RIETE registry. <i>European Journal of Internal Medicine</i> , 2016, 36, 62-66.	1.0	8
123	Conventional and Ambulatory Blood Pressure as Predictors of Retinal Arteriolar Narrowing. <i>Hypertension</i> , 2016, 68, 511-520.	1.3	20
124	Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2016, 375, 1131-1141.	13.9	692
125	Retinal microvascular diameter, a hypertension-related trait, in ECG-gated vs. non-gated images analyzed by IVAN and SIVA. <i>Hypertension Research</i> , 2016, 39, 886-892.	1.5	15
126	Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2016, 116, 747-753.	1.8	28

#	ARTICLE	IF	CITATIONS
127	Dextran sulfate triggers platelet aggregation via direct activation of PEAR1. <i>Platelets</i> , 2016, 27, 365-372.	1.1	18
128	Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial of two doses. <i>Thrombosis Research</i> , 2016, 144, 62-68.	0.8	47
129	Shear-Resistant Binding to von Willebrand Factor Allows <i>Staphylococcus lugdunensis</i> to Adhere to the Cardiac Valves and Initiate Endocarditis. <i>Journal of Infectious Diseases</i> , 2016, 213, 1148-1156.	1.9	38
130	Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. <i>Lancet Haematology</i> , 2016, 3, e228-e236.	2.2	55
131	Renal glomerular dysfunction in relation to retinal arteriolar narrowing and high pulse pressure in seniors. <i>Hypertension Research</i> , 2016, 39, 138-143.	1.5	14
132	Tissue Plasminogen Activator Coating on Implant Surfaces Reduces <i>Staphylococcus aureus</i> Biofilm Formation. <i>Applied and Environmental Microbiology</i> , 2016, 82, 394-401.	1.4	25
133	Bacterial pathogens activate plasminogen to breach tissue barriers and escape from innate immunity. <i>Critical Reviews in Microbiology</i> , 2016, 42, 866-882.	2.7	53
134	Staphylokinase Control of <i>Staphylococcus aureus</i> Biofilm Formation and Detachment Through Host Plasminogen Activation. <i>Journal of Infectious Diseases</i> , 2016, 213, 139-148.	1.9	61
135	Diastolic Left Ventricular Function in Relation to Urinary and Serum Collagen Biomarkers in a General Population. <i>PLoS ONE</i> , 2016, 11, e0167582.	1.1	22
136	<i>In Vitro</i> and <i>In Vivo</i> Model to Study Bacterial Adhesion to the Vessel Wall Under Flow Conditions. <i>Journal of Visualized Experiments</i> , 2015, , e52862.	0.2	9
137	Coronary risk in relation to genetic variation in MEOX2 and TCF15 in a Flemish population. <i>BMC Genetics</i> , 2015, 16, 116.	2.7	12
138	Edoxaban for treatment of venous thromboembolism in patients with cancer. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1268-1276.	1.8	79
139	Coagulase Activity by <i>Staphylococcus aureus</i> : A Potential Target for Therapy?. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 433-444.	1.5	35
140	Gender differences in cancer patients with acute venous thromboembolism. <i>Thrombosis Research</i> , 2015, 135, S12-S15.	0.8	13
141	Platelet endothelial aggregation receptor-1: a novel modifier of neoangiogenesis. <i>Cardiovascular Research</i> , 2015, 108, 124-138.	1.8	36
142	Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists. <i>Thrombosis Research</i> , 2015, 136, 749-753.	0.8	78
143	Urinary Proteome and Systolic Blood Pressure as Predictors of 5-Year Cardiovascular and Cardiac Outcomes in a General Population. <i>Hypertension</i> , 2015, 66, 52-60.	1.3	33
144	Long-term Clinical Outcomes of Splanchnic Vein Thrombosis. <i>JAMA Internal Medicine</i> , 2015, 175, 1474.	2.6	180

#	ARTICLE	IF	CITATIONS
145	A RIETE registry analysis of recurrent thromboembolism and hemorrhage in patients withÂcatheter-related thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2015, 3, 243-250.e1.	0.9	28
146	Dabigatran-Associated Spontaneous Acute Cervical Epidural Hematoma. <i>World Neurosurgery</i> , 2015, 83, 257-258.	0.7	18
147	Duration of anticoagulation after venous thromboembolism in real world clinical practice. <i>Thrombosis Research</i> , 2015, 135, 666-672.	0.8	62
148	Characteristics and Determinants of the Sublingual Microcirculation in Populations of Different Ethnicity. <i>Hypertension</i> , 2015, 65, 993-1001.	1.3	24
149	A Human Platelet Receptor Protein Microarray Identifies the High Affinity Immunoglobulin E Receptor Subunit Î± (FcÎ±R1Î±) as an Activating Platelet Endothelium Aggregation Receptor 1 (PEAR1) Ligand *. <i>Molecular and Cellular Proteomics</i> , 2015, 14, 1265-1274.	2.5	62
150	Pulmonary embolism: Epidemiology and registries. <i>Presse Medicale</i> , 2015, 44, e377-e383.	0.8	20
151	Inactive Matrix Gla Protein Is Causally Related to Adverse Health Outcomes. <i>Hypertension</i> , 2015, 65, 463-470.	1.3	84
152	Abstract 16418: Reinitiation of Antithrombotic Therapy After Emergency Procedures or After an Uncontrolled or Life Threatening Bleeding Event. Initial Experience From the Re-verse Ad Trial. <i>Circulation</i> , 2015, 132, .	1.6	1
153	Direct Oral Anticoagulants for Acute Venous Thromboembolism. <i>Circulation</i> , 2014, 129, 725-727.	1.6	12
154	Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants. <i>Thrombosis Journal</i> , 2014, 12, 21.	0.9	78
155	Plasminogen activation by staphylokinase enhances local spreading of <i>S. aureus</i> in skin infections. <i>BMC Microbiology</i> , 2014, 14, 310.	1.3	36
156	Adhesion of <i>Staphylococcus aureus</i> to the vessel wall under flow is mediated by von Willebrand factorâ€“binding protein. <i>Blood</i> , 2014, 124, 1669-1676.	0.6	96
157	Active PAI-1 as marker for venous thromboembolism: Caseâ€“control study using a comprehensive panel of PAI-1 and TAFI assays. <i>Thrombosis Research</i> , 2014, 134, 1097-1102.	0.8	23
158	The urinary proteome as correlate and predictor of renal function in a population study. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 2260-2268.	0.4	57
159	Antithrombotic Treatment and Outcomes of Splanchnic Vein Thrombosis in an International Prospective Registry: Results of 2-Year Follow-up. <i>Blood</i> , 2014, 124, 592-592.	0.6	0
160	Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis. <i>Blood</i> , 2014, 124, LBA-1-LBA-1.	0.6	0
161	Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2013, 369, 1406-1415.	13.9	1,607
162	The Role of Staphylothrombin-Mediated Fibrin Deposition in Catheter-Related <i>Staphylococcus aureus</i> Infections. <i>Journal of Infectious Diseases</i> , 2013, 208, 92-100.	1.9	59

#	ARTICLE	IF	CITATIONS
163	Central Systolic Augmentation Indexes and Urinary Sodium in a White Population. <i>American Journal of Hypertension</i> , 2013, 26, 95-103.	1.0	17
164	Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement. <i>Thrombosis and Haemostasis</i> , 2013, 109, 1091-1098.	1.8	13
165	Fibrin formation by staphylothrombin facilitates <i>Staphylococcus aureus</i> -induced platelet aggregation. <i>Thrombosis and Haemostasis</i> , 2012, 107, 1107-1121.	1.8	62
166	Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International Registry. <i>Blood</i> , 2012, 120, 499-499.	0.6	3
167	Anti-thrombotic therapy in infective endocarditis. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 1203-1219.	0.6	26
168	Tolerability and pharmacokinetics of TB-402 in healthy male volunteers. <i>Clinical Therapeutics</i> , 2010, 32, 1205-1220.	1.1	22
169	Dabigatran Inhibits <i>Staphylococcus aureus</i> Coagulase Activity. <i>Journal of Clinical Microbiology</i> , 2010, 48, 4248-4250.	1.8	43
170	Carotid intima-media thickness: more than a research tool?. <i>Acta Cardiologica</i> , 2010, 65, 59-66.	0.3	6
171	A pilot trial of microplasmin in patients with long-term venous access catheter thrombosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 477-481.	1.0	6
172	Hemostasis and inflammation: two of a kind?. <i>Thrombosis Journal</i> , 2009, 7, 15.	0.9	52
173	A dose-finding clinical trial of staphylokinase SY162 in patients with long-term venous access catheter thrombotic occlusion. <i>Journal of Thrombosis and Thrombolysis</i> , 2007, 24, 1-5.	1.0	11
174	Phase I Clinical Trial of a Novel, Long-Acting Antithrombotic Drug: A Human Monoclonal Antibody Partially Inhibiting FVIII Activity.. <i>Blood</i> , 2007, 110, 312-312.	0.6	5
175	Antiplatelet treatment in peripheral arterial disease. , 2001, , 458-470.		0
176	Circulating Oxidized LDL Is a Useful Marker for Identifying Patients With Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 844-848.	1.1	469